These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7588086)

  • 1. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
    Spencer CM; Goa KL
    Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atovaquone: a review.
    Haile LG; Flaherty JF
    Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
    Hughes WT
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
    Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
    N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atovaquone: a new antipneumocystis agent.
    Artymowicz RJ; James VE
    Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
    Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ
    Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
    Zarkin GA; Bala MV; Wood LL; Bennett CL; Simpson K; Dohn MN
    Pharmacoeconomics; 1996 Jun; 9(6):525-34. PubMed ID: 10160480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing PCP therapy.
    Torres G; Cadman J
    GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients.
    Rosenberg DM; McCarthy W; Slavinsky J; Chan CK; Montaner J; Braun J; Dohn MN; Caldwell PT
    AIDS; 2001 Jan; 15(2):211-4. PubMed ID: 11216929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
    Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P
    J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
    Deresinski SC
    Semin Respir Infect; 1997 Jun; 12(2):79-97. PubMed ID: 9195673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.
    Goodwin SD; Fish DN
    Am J Health Syst Pharm; 1995 Nov; 52(21):2460-2. PubMed ID: 8564614
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.
    Hughes WT; LaFon SW; Scott JD; Masur H
    J Infect Dis; 1995 May; 171(5):1295-301. PubMed ID: 7751706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia.
    White A; LaFon S; Rogers M; Andrews E; Brown N
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):280-5. PubMed ID: 7788426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy and prevention of pneumocystis carinii pneumonia].
    Goebel FD; Bogner JR
    Internist (Berl); 1995 Dec; 36(12):1150-5. PubMed ID: 8567220
    [No Abstract]   [Full Text] [Related]  

  • 16. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
    Korraa H; Saadeh C
    South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
    El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
    N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration.
    Cotton D
    AIDS Clin Care; 1995 Jul; 7(7):62. PubMed ID: 11362554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia.
    Epstein LJ; Mohsenifar Z; Daar ES; Yeh V; Meyer RD
    Am J Med Sci; 1994 Jul; 308(1):5-8. PubMed ID: 8010339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
    Brun-Pascaud M; Chau F; Rajagopalan-Levasseur P; Derouin F; Girard PM
    J Eukaryot Microbiol; 1996; 43(5):14S-15S. PubMed ID: 8822822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.